Literature DB >> 30882246

Representation of Patients With Cardiovascular Disease in Pivotal Cancer Clinical Trials.

Janice Bonsu1, Lawrence Charles1, Avirup Guha1, Farrukh Awan2, Jennifer Woyach2, Vedat Yildiz3, Lai Wei3, Hani Jneid4, Daniel Addison1.   

Abstract

Entities:  

Keywords:  United States Food and Drug Administration; cancer; cardiovascular disease; clinical trials as topic; underrepresentation

Mesh：

Substances：

Year:  2019        PMID： 30882246      PMCID： PMC8244729          DOI： 10.1161/CIRCULATIONAHA.118.039180

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  4 in total

Review 1.  Cardiovascular Toxic Effects of Targeted Cancer Therapies.

Authors:  Javid J Moslehi
Journal:  N Engl J Med       Date:  2016-10-13       Impact factor: 91.245

2.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

3.  Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10 years older without cardiovascular morbidity.

Authors:  Maryska L G Janssen-Heijnen; Karolina Szerencsi; Saskia A M van de Schans; Huub A A M Maas; Jos W Widdershoven; Jan Willem W Coebergh
Journal:  Crit Rev Oncol Hematol       Date:  2009-12-29       Impact factor: 6.312

4.  21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine.

Authors:  Calvin Chen Sheng; Laleh Amiri-Kordestani; Todd Palmby; Thomas Force; Charles C Hong; Joseph C Wu; Kevin Croce; Geoffrey Kim; Javid Moslehi
Journal:  JACC Basic Transl Sci       Date:  2016-08
  4 in total
  12 in total

1.  Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies.

Authors:  Janice M Bonsu; Avirup Guha; Lawrence Charles; Vedat O Yildiz; Lai Wei; Brandee Baker; Jonathan E Brammer; Farrukh Awan; Maryam Lustberg; Raquel Reinbolt; Eric D Miller; Hani Jneid; Patrick Ruz; Rebecca R Carter; Michael W Milks; Electra D Paskett; Daniel Addison
Journal:  J Am Coll Cardiol       Date:  2020-02-18       Impact factor: 24.094

2.  Prevalence of Cardiovascular Disease in Patients With Potentially Curable Malignancies: A National Registry Dataset Analysis.

Authors:  Nicolò Matteo Luca Battisti; Catherine A Welch; Michael Sweeting; Mark de Belder; John Deanfield; Clive Weston; Michael D Peake; David Adlam; Alistair Ring
Journal:  JACC CardioOncol       Date:  2022-06-21

3.  Comparison of Clinical Characteristics Between Clinical Trial Participants and Nonparticipants Using Electronic Health Record Data.

Authors:  James R Rogers; Cong Liu; George Hripcsak; Ying Kuen Cheung; Chunhua Weng
Journal:  JAMA Netw Open       Date:  2021-04-01

Review 4.  Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data.

Authors:  Jennifer M Kwan; Evangelos K Oikonomou; Mariana L Henry; Albert J Sinusas
Journal:  Front Cardiovasc Med       Date:  2022-03-15

Review 5.  Cardiovascular Safety Assessment in Cancer Drug Development.

Authors:  Ohad Oren; Tomas G Neilan; Michael G Fradley; Deepak L Bhatt
Journal:  J Am Heart Assoc       Date:  2021-12-16       Impact factor: 6.106

Review 6.  Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review.

Authors:  Claire Glen; Yun Yi Tan; Ashita Waterston; Thomas R Jeffry Evans; Robert J Jones; Mark C Petrie; Ninian N Lang
Journal:  JACC CardioOncol       Date:  2022-03-15

7.  Ischaemic heart disease and Cancer: competing malignant conditions.

Authors:  Alexandra C Murphy; Anoop N Koshy; Matias B Yudi
Journal:  BMC Cardiovasc Disord       Date:  2020-05-27       Impact factor: 2.298

Review 8.  Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies.

Authors:  Michael A Biersmith; Matthew S Tong; Avirup Guha; Orlando P Simonetti; Daniel Addison
Journal:  J Am Heart Assoc       Date:  2020-01-21       Impact factor: 5.501

9.  Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Authors:  Rudolf A de Boer; Jean-Sébastien Hulot; Carlo Gabriele Tocchetti; Joseph Pierre Aboumsallem; Pietro Ameri; Stefan D Anker; Johann Bauersachs; Edoardo Bertero; Andrew J S Coats; Jelena Čelutkienė; Ovidiu Chioncel; Pierre Dodion; Thomas Eschenhagen; Dimitrios Farmakis; Antoni Bayes-Genis; Dirk Jäger; Ewa A Jankowska; Richard N Kitsis; Suma H Konety; James Larkin; Lorenz Lehmann; Daniel J Lenihan; Christoph Maack; Javid J Moslehi; Oliver J Müller; Patrycja Nowak-Sliwinska; Massimo Francesco Piepoli; Piotr Ponikowski; Radek Pudil; Peter P Rainer; Frank Ruschitzka; Douglas Sawyer; Petar M Seferovic; Thomas Suter; Thomas Thum; Peter van der Meer; Linda W Van Laake; Stephan von Haehling; Stephane Heymans; Alexander R Lyon; Johannes Backs
Journal:  Eur J Heart Fail       Date:  2020-11-12       Impact factor: 15.534

10.  Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis.

Authors:  Giacomo Tini; Edoardo Bertero; Alessio Signori; Maria Pia Sormani; Christoph Maack; Rudolf A De Boer; Marco Canepa; Pietro Ameri
Journal:  J Am Heart Assoc       Date:  2020-08-31       Impact factor: 5.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.